We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

126 hedge funds and large institutions have $518M invested in Progenics Pharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more call options, than puts

Call options by funds: $2.19M | Put options by funds: $1.05M

82% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 17

36% more capital invested

Capital invested by funds: $380M → $518M (+$138M)

10% more funds holding

Funds holding: 115126 (+11)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

18% less repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 44

Holders
126
Holders Change
+11
Holders Change %
+9.57%
% of All Funds
3.15%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
31
Increased
36
Reduced
44
Closed
17
Calls
$2.19M
Puts
$1.05M
Net Calls
+$1.14M
Net Calls Change
+$693K
Name Holding Trade Value Shares
Change
Change in
Stake
Fisher Asset Management
51
Fisher Asset Management
Washington
$683K -$212K -28,635 -27%
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$672K +$31.1K +4,204 +6%
PPA
53
Parametric Portfolio Associates
Washington
$655K +$561K +75,836 New
State Board of Administration of Florida Retirement System
54
State Board of Administration of Florida Retirement System
Florida
$615K +$191K +25,801 +57%
AA
55
ALPS Advisors
Colorado
$582K +$498K +67,319 New
HK
56
Horizon Kinetics
New York
$581K
CCM
57
Cadence Capital Management
Massachusetts
$575K -$900K -121,751 -65%
ProShare Advisors
58
ProShare Advisors
Maryland
$496K +$47.6K +6,445 +13%
BA
59
BlackRock Advisors
Delaware
$471K +$131K +17,688 +48%
CHAM
60
Clear Harbor Asset Management
Connecticut
$454K -$5.99K -810 -2%
VKH
61
Virtu KCG Holdings
New York
$422K +$96K +12,991 +36%
MLICM
62
Metropolitan Life Insurance Company (MetLife)
New York
$397K -$22.9K -3,102 -6%
RJA
63
Raymond James & Associates
Florida
$380K +$325K +44,024 New
UBS Group
64
UBS Group
Switzerland
$375K +$105K +14,261 +49%
NFA
65
Nationwide Fund Advisors
Ohio
$367K -$12.6K -1,699 -4%
Squarepoint
66
Squarepoint
New York
$350K +$218K +29,460 +265%
Stifel Financial
67
Stifel Financial
Missouri
$348K +$113K +15,294 +61%
AIG
68
American International Group
New York
$346K -$769 -104 -0.3%
Barclays
69
Barclays
United Kingdom
$340K +$120K +16,266 +70%
NIT
70
NumerixS Investment Technologies
British Columbia, Canada
$303K +$259K +35,100 New
Manulife (Manufacturers Life Insurance)
71
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$299K -$133K -18,053 -34%
GT
72
Glenmede Trust
Pennsylvania
$292K +$251K +33,907 New
CCMH
73
Cornerstone Capital Management Holdings
New York
$289K +$248K +33,500 New
SEI Investments
74
SEI Investments
Pennsylvania
$276K +$236K +31,900 New
VOYA Investment Management
75
VOYA Investment Management
Georgia
$274K

PGNX Hedge Fund Activity: Q4 2016 in Review

126 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2016, worth a combined $518M — up 36% from $380M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new PGNX positions and 17 closed out — a net gain of 14 holders — while 36 added to existing stakes and 44 trimmed.

The largest buyer was Eagle Asset Management, opening a new position worth an estimated $19.7M. The largest seller was Millennium Management, cutting an estimated $15.4M.

  • 126 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2016, up from 115 in Q3 2016.
  • Funds reported $518M of Progenics Pharmaceuticals Inc stock for Q4 2016, up 36% quarter-over-quarter.
  • 31 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2016 and 17 closed out, a net change of +14 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2016 was Eagle Asset Management, an estimated $19.7M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2016 was Millennium Management, an estimated $15.4M sold.

Based on aggregated 13F filings for Q4 2016.